Last edition
News about
Medtronic Signs USD 550 Million Deal To Buy Scientia Vascular
Medtronic plc has entered into a definitive agreement to acquire Scientia Vascular for USD 550 million, as the medical technology giant looks to strengthen its neurovascular portfolio and expand capabilities in stroke treatment.
A multi-institutional study published in the Journal for ImmunoTherapy of Cancer finds that an AI-based imaging biomarker can predict immunotherapy outcomes and detect early treatment response in lung cancer patients.
Agilent to Acquire Biocare Medical
Agilent Technologies has agreed to acquire Biocare Medical, expanding its pathology portfolio with complementary antibodies, reagents and instruments. The acquisition is expected to strengthen Agilent’s revenue growth, margin profile and non-instrument revenue mix from the first year.
Citius Oncology reports positive Phase I data showing encouraging safety and response rates for LYMPHIR combined with Keytruda in recurrent gynecologic cancers, supporting further Phase II evaluation.
EDQM Audit Finds Anuh Pharma Facility Compliant
Anuh Pharma has cleared a Good Manufacturing Practice (GMP) milestone following a successful audit by the European Directorate for the Quality of Medicines & HealthCare at its bulk drug manufacturing facility in Tarapur, Maharashtra, the company said in a stock exchange filing.
GenomOncology Partners with WeTrials to Accelerate Clinical Trial Access for CNS Cancer Patients
GenomOncology and WeTrials collaborate to streamline clinical trial enrollment for Central Nervous System Cancer patients, integrating genomic reports with AI-driven patient engagement tools through expanded partnership with Belay Diagnostics.
Fujitsu and DT-Axis Partner to Accelerate Development of Software as Medical Devices
Fujitsu and DT-Axis sign MoU to support development, regulatory approval and commercialisation of Software as Medical Devices, strengthening digital health innovation and clinical adoption in Japan.
IDEAYA Biosciences Enrolls First Patient in Phase I Trial of IDE892 for MTAP-Deleted Solid Tumours
IDEAYA Biosciences has initiated a Phase I clinical trial of IDE892, a PRMT5 inhibitor, for MTAP-deleted cancers including Non-Small Cell Lung Cancer and Pancreatic Cancer.
National Medical Products Administration approves IND application for HBM7575/SKB575, a long-acting bispecific antibody developed by Harbour BioMed and Kelun-Biotech for treating atopic dermatitis.
US Food and Drug Administration grants Priority Review to supplemental application for Enhertu to treat HER2-positive breast cancer patients with residual disease after neoadjuvant therapy, with decision expected in Q3 2026.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy